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Abstract 
 Medication safety should be at the forefront of public health initiatives. 
Medication reconciliations in primary care are key to successful, accurate, and safe 
medication use. Pharmacists are well positioned and educated to have an impact on 
medication safety by conducting reconciliations in primary care centers. Guidelines 
for training pharmacists on how to conduct medication reconciliations would be a 
useful tool for any health board striving to improve medication safety.  This study 
uses observations from pharmacists currently conducting medication reconciliations 
in primary care to propose such guidelines in the form of a flow sheet. The resulting 
flow sheet and observations are provided.  
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Introduction 
 
The Scottish Government defines medicine reconciliation as: ‘The process the 
healthcare team undertakes to ensure the list of medication, both prescribed and over 
the counter, that I am taking is exactly the same as the list I or my carers, general 
practitioner, community pharmacist and hospital team have. This is achieved in 
partnership with me through obtaining an up-to-date and accurate medication list that 
has been compared with the most recently available information and has documented 
any discrepancies, changes, deletions or additions resulting in a complete list of 
medicines accurately communicated.’(1) Medication reconciliation as defined by 
Bandrés et al. is “the process of reviewing patients complete previous medication 
regimen, comparing it with current prescriptions, and analyzing or resolving any 
discrepancies that the pharmacist does not believe to be intentional.”( 2) 
There is evidence of greater risk of error and potential harm from medicines at 
the interface between care settings. (1) Some sources have indicated that more than half 
of all medication errors occur at these transitions. (2) The Scottish Patient Safety 
Programme (SPSP) is a national initiative which aims to reduce harm.  A core work 
stream of the program is to achieve safe systems for reconciling medicines in General 
Practitioner (GP) practices following hospital discharge. (3)  A care bundle for the 
medicine reconciliation (MR) process has been developed by the SPSP. (4) NHS 
Greater Glasgow and Clyde tested the care bundle on a small scale and followed with 
large scale implementation.  Of the 200 GP practices responding, 85% reported the 
MR work had improved patient safety and 80% reported that it had led to improved 
practice processes. (4) Although the process required additional time, this was offset by 
time saved correcting medication issues at a later stage. Quality improvement 
methodology was used in a UK hospital with the aim of reducing discrepancies in 
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transcribing medication at admission to hospital and improving documentation and 
communication of MR on hospital discharge. Immediate discharge letters and clinic 
letters serve as the avenue of communication between the patient’s primary care 
provider and the hospital or specialty clinic responsible for discharge. This 
communication is crucial to the proper management of the patient’s medications and 
highlights a strikingly obvious potential failure in continuity of care. Post study audit 
of discharge summaries showed reliable documentation improved from 49.2% to 
85.2%.(5) Local SPSP audit data reported a reduction in error rate on hospital 
immediate discharge letters (IDLs) of 87% and an increase in accuracy following a 
change in the structure of the IDL template and addition of a second senior doctor 
signature.(6)  This supports the use of IDLs for effective transitions; if the process of 
using the information provided can be effectively implemented in primary care.  
Evaluation of the medication reconciliation process in primary care to identify 
and categorize the care issues arising from inpatient and outpatient immediate 
discharge letters is important for ensuring cost-effective and safe transitions of care in 
Scotland. Increasingly, pharmacists are contributing to the medication reconciliation 
process in GP practices around Scotland.  However, it has been shown that 
identification of errors or discrepancies does not always lead to an improvement in 
workload. (7) Thus, the NIH in Scotland has resolved to ensure proper implementation 
of a medication reconciliation system. The efficiency of this system could be 
enhanced following a review of the process of writing, sending, receiving, and acting 
upon clinic letters and IDLs as part of the medication reconciliation process. A 
medicine reconciliation guideline in primary care in the form of a flowchart 
incorporating the SPSP care bundle could lead to improved transitions, workload, and 
patient outcomes. This flow diagram was developed as a guideline for all primary care 
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pharmacists carrying out MR in GP practices. Through careful evaluation of the 
logistics and actions needed to provide accurate medication reconciliation for patients, 
a standardized process will be recommended for all GP practices.  Standardization of 
this process increases the level of patient care by reducing medication errors, 
increasing the validity of the patient’s medication list found in GP records upon 
discharge from outpatient clinics and inpatient stays, and improving workflow in 
primary care clinics across the NIH.  
The issues and processes discussed above are of immense public health 
importance for many reasons. First, the primary care sector of healthcare is well 
known for deficiencies in access.  Additionally, it is well known that transitions of 
care between different healthcare environments such as from hospitals and medical 
centers to the general practitioners’ offices lead to medication errors and in return 
unnecessary healthcare dollar expenditures relayed to errors.  Pharmacist’s facilitated 
cost savings has been demonstrated through medication reconciliations, collaborative 
drug therapy management, and therapeutic alternative substitutions.(8) Additionally, it 
has been shown that pharmacists in close working relationships with physicians in the 
inpatient setting can lead to a decrease length of stay and avoidance of preventable 
adverse drug reactions.(9)  A study examining medication reconciliation from Spain 
found that physicians agreed with pharmacists clinical judgment for evaluating errors 
93% of the time.(2) Furthermore, it has been shown that pharmacist led interventions 
have been more effective at identifying clinically impactful discrepancies than usual 
methods for transitions of care.(10,11) Due to the potential benefit pharmacists can have 
on transitions of care, adverse drug events, medication errors, time, and cost savings, 
a stream of pharmacists moving towards more clinical roles in the primary care setting 
should be a natural public health objective. This is supported by Ensing et al., who 
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reported that close collaboration between pharmacists and physicians integrated 
across many settings and locations is beneficial for identifying potentially serious 
medication errors. (12) Furthermore, proper implementation of pharmacists in these 
primary care setting is essential for ensuring public health benefit.  
Aim 
To undertake an evaluation of the medicine reconciliation process in primary care in a 
Scottish health board.  
Objectives 
1. Design a medication reconciliation procedure specific to the GP Practices 
where pharmacist driven reconciliation is undertaken. 
2. Design and pilot a data collection tool to record information from observations 
of general practitioners and pharmacists undertaking the medication 
reconciliation process. 
3. Improve the efficiency and accuracy of pharmacist led medication 
reconciliation by providing standardized guidelines in the form of a flow chart 
for the process of medication reconciliation based on study results.  
4. To record care issues identified in the medication reconciliation process, 
categorize them, and rate their severity of care issues using recognized tools. 
Design 
The study design was a prospective observation of pharmacists’ and general 
practitioners’ medication reconciliation processes within the primary care setting in a 
Scottish Health Board. Potential medication reconciliations were identified in GP 
practices as IDLs from hospital inpatient admissions or outpatient clinic letters 
received at the practice. 
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Local approval was sought from the Pharmacy Quality Improvement Team of 
NHS Lothian.  Individual GP and pharmacist permission for observation of the 
reconciliation process was requested, those who accepted completed an agreement 
form (appendix 1) and a copy of the protocol was provided. All discharges from 
clinics and hospitals to the identified GP practices were eligible. All pharmacists were 
chosen on a convenience and willingness basis. Patients were excluded if the hospital 
stay resulted in death or if the patient was admitted and discharged with no 
medications. Letters or discharges that were deemed duplicates were counted, but left 
out of any statistical information. 
Methods 
A template (appendix 2) was designed to incorporate all elements involved in 
the MR process in GP practices. A guideline was incorporated and the template 
completed for the individual GP practices where pharmacists were currently 
preforming MRs to form a procedure specific to primary care pharmacy practice in 
the identified GP practices. 
A data collection tool was designed and piloted through observation of a 
pharmacist undertaking MR in one GP practice. Next, data was collected over a three-
week period in four GP practices through observance by the investigator of four 
pharmacists with the aim of collecting approximately 100 patient MR episodes. GP 
MR was intended to be observed in practices where there is no pharmacist 
contribution to the MR process. The tool was targeted at collecting process data 
including: time spent to complete a MR event, date of IDL received and date of 
discharge or clinic attendance, number of medicines per MR event, number of MR 
events requiring follow up and type of follow up, whether patient has medication 
compliance aid. The tool used can be found in appendix 3. 
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Process totals and percentages were reported and can be found in appendix 4. 
Data from pharmacist MR and GP MR were compared and contrasted. A report was 
produced and an oral presentation of results was made to the primary and secondary 
care pharmacy team meeting. Results were obtained by weighting each of the four 
practices equally in order to avoid skewing of the data based on unequal sample sizes. 
The tool recorded the number of care issues identified by pharmacists and GPs 
in the MR process for each patient. The investigator subsequently categorized the 
issues and rated the severity (minor, significant, serious, and potentially lethal) 
according to the EQUIP5 criteria. Significant and potentially lethal issues were 
recorded in a situation, background, assessment, recommendation (SBAR) format. 
Care issue categorization and severity rating were peer reviewed by the supervisor.  
Results 
The template for developing the necessary procedures during MR was 
proposed in the beginning of the study. This template included all aspects of the 
suspected MR process map, this document can be found in appendix 2. 
The data collection tool can be found in appendix 3.  This tool was developed 
using the template and then piloted successfully based on observation of five MRs 
tasked to a pharmacist from one GP practice and then updated accordingly for this 
study. After three weeks of data collection, 93 total MRs were observed.  There were 
nine duplicates found in this sample (9.6%) leaving 84 total observations. Of the four 
GP practices surveyed, the distribution for contribution to our study was not equal. 
This is exemplified in the following chart: 
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Table 1: Overview of Observations 
Practice Number Number of Observations 
Practice 1 9 
Practice 2 14 
Practice 3 21 
Practice 4 40 
Total 84 
 
There were no results available from observation of GPs as this aspect of the 
intended study was not successfully completed. There was a retrospective analysis of 
seven MRs completed by GPs in which 0% of the changes made by the GP were 
noted in the patient’s chart using the MR read-code.  
The next section of results concentrates on quantitative workflow measures. 
Starting with the process of letters being received by the GP practices, notably the 
largest delay in information was seen between the patient’s visit or discharge and the 
day their letter was written by the discharging entity (5.2 ± 4.6 days on average). The 
second longest delay was between the day the letter was written and when it was 
received by the GP practice (2.6 ± 0.3 days on average). Lastly, the shortest delay was 
found between the day the letter was received by the practice and the day it was 
processed by a pharmacist (1.3 ± 0.8 days on average). Additionally, pharmacists 
completed the medication reconciliations within 48 hours of the letter being received 
about 91% of the time on average.  
Next, pharmacists’ completion of the MR process was timed.  The average 
amount of time for processing a discharge letter was 7.0 ± 0.7 minutes, while the 
average for a clinic letter was 9.6 ± 3.6 minutes. Interestingly, Practice 1, a sample of 
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8 observations, had an average clinic letter completion time of 14.8 minutes and no 
discharge letters in the sample, this was not seen in the observations from other 
practices.  
Qualitative process validation and quality assurance results were gathered 
using the tool developed for this study. First, the proportion of medication 
reconciliations which found an error in the clinic or discharge letter varied greatly. 
Changes were made to the patient’s chart 82.2% of the time between the practices. If 
there were no changes to be noted on the chart the observation was not counted 
towards our calculation of the proportion of MRs in which pharmacists added the 
proper changes to the chart. Importantly, the medication reconciliation read-code was 
used on average 92.3% of the time. 
Next, it was found that whether or not the pharmacist analyzed the patient’s 
repeat list for other changes to be made unrelated to the letter received varied greatly 
between practices. This is evident in that Practice 4 attempted to remove outdated 
repeats 100% of the time, while Practice 2 analyzed the other repeats on 46.1% of the 
medication reconciliations.  Similarly, allergies were checked by some practices, 
100% of the time by Practice 4, but never by practice 2 at 0%. Lastly, patients and 
caregivers were contacted 33.25% of the time on average.  
MRs in which errors were found were forwarded to GPs for further assistance 
18.3% of the time. Pharmacists exercised their clinical decision making skills on 
38.7% of the MRs with in some capacity. Notably, the amount of clinical decision 
making varied with 71.4% of the errors at Practice 4 resolved by the pharmacist 
compared to 16.7% of those at Practice 1. There are no results from any SBARs 
(situation, background, assessment, recommendation) for the issues encountered as 
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the information was not as readily available as anticipated. A more detailed 
breakdown of the results can be found in appendix 4. 
Discussion 
The template for conducting this project was useful for developing both the 
data collection tool and final flow diagram. The data collection tool was useful for the 
purposes it was designed. However, some of the findings in this study cannot be 
explained using statistics. Specifically, it became extremely difficult to understand the 
process utilized by GPs to perform medication reconciliations.  This is in part due to 
the technique the GPs utilize in terms of time management with MRs. The observed 
standard for GPs is that MRs fit into random slots of spare time, making planned 
observation for study purposes nearly impossible. Upon speaking with GPs it became 
clear that they tend to make all necessary medication changes highlighted in the letters 
received, without adding any notes in the patient’s chart.  Additionally, GPs do not 
use the medication reconciliation read-code. The importance of the read-code is that it 
enables fellow professionals to search the patient’s chart regarding the information 
contained in the letter where the changes originated. Without these events coded into 
the patient chart, finding the letter from which the changes were made involves an 
inefficient search through the Docman system.  The Docman system holds electronic 
copies of letters regarding that patient throughout the course of their care, thus it can 
be cumbersome to find specific documents. This was somewhat supported by the 
retrospective analysis of seven MRs completed by GPs. Illustrating the importance of 
this read-code to GPs could be a beneficial exercise. 
Scottish patient safety program guidelines note all letters should be processed 
within 48 hours of being received. Pharmacists managed to reach this guideline 91% 
of the time. The greatest time lag in the process is between the patient visit or 
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discharge and the day the letter is actually written. There are no guidelines in place to 
ensure efficient writing and delivery of these letters for each patient visit.  It is 
paradoxical to have guidelines urging GP practices to process a letter within 48 hours 
when it’s possible that letter was written two weeks after the patient’s visit or 
discharge. This sheds light on future study ambitions in order to streamline the MR 
processing between healthcare locations. 
The time for pharmacists to complete MRs was found to be very similar across 
three of the practices with a range of 6.2-7.5 minutes for discharge letters and 6.7-8.9 
for clinic letters. The results gathered do become confounded by Practice 1, which had 
an average completion time of 14.8 minutes. Notably, observations of clinic letters 
and no IDLs were obtained at this practice.  Possible implications of this are that the 
overall pharmacists’ time spent on average for clinic letters is skewed by this practice, 
while the IDL average is not. This difference could account for the 9.6-minute 
average for clinic letters versus the 7.0-minute average for IDLs. Explanations for this 
possible anomaly include a small sample size since Practice 1 was the smallest sample 
in the study. Another explanation could be that the pharmacist in that practice is not as 
experienced with MR.  However, it is especially worth noting that the cases could 
have been more complicated on average, which may be reflected in the rate of errors 
found being more than double that of any other practice. Interestingly, 72.7% of errors 
in the study were found in clinic letters. More information on the errors and their 
severity are highlighted in appendix 6 and will be discussed below.  
Our findings identified pharmacists as important members of the primary care 
team through their dedication to updating patients’ charts. It was clear early on that 
pharmacist’s consistently use the MR read-code (92.3%). In some cases, pharmacists 
would input the read-code and letter information after a GP had already seen the letter 
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and made changes. This illuminates the GPs tendency to make changes, but not input 
the letter details so they could be easily tracked.  
Pharmacists did seem to diverge in the process upon continued evaluation. The 
data showed that some pharmacist always checked and attempted to update allergy 
information during the MR process while some never did. The same was found for 
pharmacist’s ensuring the patient’s repeat list could not be updated. The repeat list 
that has been referred to thus far may be misunderstood by healthcare professionals in 
the United States; however, it simply refers to the medications a patient is intended to 
get every month, similar to a list of maintenance medications. However, medications 
not intended to be part of the patient’s medication list chronically are often added to 
the repeat list.  This mistake occurs when the patient calls the GP for a given 
medication, that they were meant to be taking acutely, to be filled again.  Then due to 
time constraints a GP may never fully review whether or not that patient should be 
taking the medication chronically, unfortunately a “repeat request” may be the only 
information seen, so they give them another month’s supply to avoid further 
conflict/disgruntlement from the patient. Eventually, it becomes easier for a given 
medication to be added to the patient’s repeat list than it is to deal with the repeat 
(refill) request monthly. Once the medication is on the patient’s repeat list, they are 
able to go to any pharmacy and obtain the medication as long as their number of 
repeats does not run out. This seems very similar to the practice in the United States; 
however, providers in Scotland will often add “999” when they are prompted for the 
number of repeats as the medication is being added to the repeat list. Thus, the patient 
may receive a medication, for years that was meant to be used only once for an acute 
event, from their pharmacy upon request without this medication being reviewed by 
any professional regularly. Pharmacists have the ability to play an important role in 
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combating the repeat issue. The pharmacist from Practice 4 always attempted to 
“clean up” the repeat list, while this was done less than 50% of the time by others. 
These findings illustrate a need for a standardized procedure and teaching guideline.  
The last notable observation was that pharmacists perform MR were calling 
their patients regarding the changes made to their medications a small percentage of 
the time. This finding led to the crucial action of contacting the patient with all 
changes being a required step in the Medication Reconciliation Flow Sheet. Most of 
the hesitation surrounding this contact came from pharmacists not wanting to be 
redundant.  However, contacting their patients with medication changes should be 
seen as the duty of any pharmacist, regardless of who contacted them previously.  
This could build the pharmacist-patient relationship; as well as, plant pharmacists as 
part of the foundation for improved primary care services.  
These observations led to the development of the Medication Reconciliation 
Flow Sheet as a standardized guide to follow.  This resulting flow chart can be found 
in appendix 5. This was invented using the data found in this section to identify ways 
in which pharmacists diverge in conducting MRs in hopes of streamlining the process 
for everyone. This flow chart will serve as a guide for all future pharmacists doing 
primary care medication reconciliations in this region going forward. 
The original study protocol stated a workup including the situation, 
background, assessment, and recommendation would be completed on the most 
severe errors recorded.  However, upon practice it was clear this was impossible due 
to the nature of our observations.  The tendency when a severe issue arose was the 
initiation of follow up with the GP, clinic, hospital, or patient.  This follow up was not 
instant and thus the resulting actions taken to resolve the errors were never observed.  
This is why the errors in appendix 6 simply state the issue and what steps the 
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pharmacist then took to resolve the error. It was possible to categorize the severity of 
these errors, which can also be found in appendix 6. 
Another point of variation was how pharmacists resolved errors found during 
the MR process. Depending on the practice, some pharmacists were more likely to use 
their clinical judgment to resolve an issue, while others almost always deferred to 
GP’s judgment.  This could be explained by each individual’s comfort level at their 
practice.  Their comfort level could be reflected by length of employment at a 
particular practice and resultant familiarity with documentation systems.  This 
information could also reflect a difference in pharmacist’s knowledge or practice 
experience. This difference could not be resolved by our tool; however, further 
training focused on primary care pharmacy practice could be beneficial in future 
developments. 
Finally, pharmacists led medication reconciliation is a public health issue 
because of the potential to improve health outcomes while reducing medication 
related errors. Pharmacists’ involvement in this area of healthcare could reduce the 
number of overall prescriptions per person, reduce healthcare dollars spent on 
medications, prevent drug-drug and drug-disease interactions, and promote overall 
effective and safe medication use by patients in the community. Interestingly, this 
study may have difficulty impacting the current system in the United States. One 
barrier is the small number of pharmacists in primary care centers. (13) Community 
pharmacies may not be the ideal setting for medication reconciliation services due to 
workflow issues. (14)  Two examples of these workflow issues could include barriers in 
communication between the pharmacist and a patient’s primary care provider or 
simply pharmacies being too busy to take on additional responsibilities. Additional 
barriers to this practice coming to the United States include lack of awareness of the 
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roles pharmacists can play in primary care settings as well as laws and regulations 
surrounding pharmacists’ payment in this setting. (15) Thus, an interesting public health 
study would examine the potential pharmacists’ hold for transitions of care in the 
primary care setting of the United States.  Specifically, addressing the ways 
pharmacists take part in the primary care setting given the barriers present in the 
United States and how their role could be influenced if barriers were to change. 
Conclusion 
Pharmacists are uniquely positioned to have a lasting impact on primary care.  
The successful implementation of pharmacist driven medication reconciliation is a 
building block towards fewer medication errors, improved patient-pharmacist 
linkages, and improved pharmacist-physician relationships.  The foundation of the 
MR process should be the guidelines presented in the Medication Reconciliation Flow 
Sheet for completing this processes in the primary care setting. Standardization of 
these guidelines will ensure current and future primary care pharmacists are being 
used efficiently and at the peak of their abilities. Future studies should examine 
differences seen in pharmacists’ procedures after the implementation of these 
guidelines.  Repeating this study at the same practices in a year after the 
implementation of the Pharmacist Medication Reconciliation Flow Sheet would be a 
worthwhile endeavor. Additionally, future directions should include GPs in the 
planning and execution of studies in an attempt to unify the medication reconciliation 
process in primary care across professions. 
There are many aspects of this project that have increasing relevance to public 
health. As the discussion above indicates, pharmacist’s involvement in primary care 
offices of the Scottish health board studied has the potential to reduce errors at 
transitions of care and improve the overall level of care the patient receives. However, 
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these changes cannot be successful without proper implementation. Therefore, the 
guideline and flow sheet described in this study support a public health initiative to 
improve primary care practices by providing necessary assistance for pharmacist 
entering this area of practice.  
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Appendix 1 - Agreement Form for pharmacists 
participating in the project 
 
 
Evaluation of the Medicine Reconciliation Process in Primary 
Care 
 
 
 
-------------------------------------- (Print Name) agree to the pharmacy 
student observing my work while undertaking medicine 
reconciliation within __________________ (GP Practice) as part of 
data collection of the above named evaluation project. 
I have read and understood the protocol. 
 
Signature___________________ 
Date________________________ 
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Appendix 2 - Original NHS Medication 
Reconciliation Template Guideline  
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Appendix 3- 
Observation Tool 
 
 
 
 
Med Rec Tool
1. Clinic Name
Mark only one oval.
 Eskbridge
 Riverside
 Trenent
 Bonnyrig
 Murryfield 1
2. Who implemented the workflow?
Mark only one oval.
 Doctor
 Pharmacist
 Admin Staff
3. Start Time
 
Example: 8:30 AM
4. Clinic letter or Discharge?
Mark only one oval.
 Clinic
 Discharge
 Duplicate
5. Appointment/Discharge Date
 
Example: December 15, 2012
6. Date Written
 
Example: December 15, 2012
7. Date Received
 
Example: December 15, 2012
8. Date Processed
 
Example: December 15, 2012
  
Appendix 4- Results from Observations 
 
 
 
 
 
 
 
 
 
 
Practice Name Practice 1 Practice 2 Practice 3 Practice 4 Pharmacists Avg. 
Average days between visit and 
letter/IDL written 5.6 
0.8 (outlier of 
48) 10.9 3.6 5.2 
Average days between letter/IDL 
written and received by the surgery  3.0 2.4 2.5 2.6 2.6 
Average days between letter/IDL 
received and processed 2.3 0.5 1.0 1.4 1.3 
Average time to complete a MR for 
the practice (minutes) 14.8** 7.9 7.8 6.9 7.5 
Average time to complete the MR 
process - Clinic letter (minutes) 14.8 8.9 7.9 6.7 9.6 
Average time to complete the MR 
process - IDL (minutes) N/A 6.2 7.4 7.5 7.0 
Proportion of MR with errors found 
in the letter/IDL during the Process 44.44% 21.43% 14.29% 15.00% 23.79% 
Percentage of MR with more than 
10 medications on the patients 
repeat list (duplicates removed) 44.44% 42.86% 28.57% 22.50% 34.59% 
Percentage of MR in which changes 
were made to the Pt's medication 
list (if no changes MR excluded) 66.67% 77.78% 84.21% 100.00% 82.16% 
Were the repeats analysed during 
the MR? 88.89% 46.15% 90.48% 100.00% 81.38% 
Was the patient or caregiver 
contacted with changes? 55.56% 33.33% 13.33% 30.77% 33.25% 
Were allergies checked during the 
MR? 12.50% 0.00% 50.00% 100.00% 40.63% 
Was the MR read-coding 
completed? 88.89% 92.86% 90.00% 97.50% 92.31% 
MR forwarded to GP with questions 
about prescriptions? 44.44% 14.29% 9.52% 5.00% 18.31% 
Clinical decision made by 
pharmacist if there was an error 16.67% 33.33% 33.33% 71.43% 38.69% 
Was the MR completed within 48hrs 
of receiving the letter or IDL? 88.89% 100.00% 95.24% 80.00% 91.03% 
Percentage of letters/IDLs in 
workflow found to be duplicates 10.00% 17.65% 8.70% 6.98% 10.83% 
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Appendix 5 - Medication Reconciliation Flow Chart 
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Appendix 6 – Errors found during observation of MRs 
 
Pt/Type Problem Solution NCC MERP EQUIP 
1  
(Clinic 
Letter) 
Unclear directions about how to increase 
the patient’s anti-epileptic medications 
to the desired dose 
Pharmacist sent to 
GP for follow up 
 
Category E Serious 
2  
(Clinic 
Letter) 
Discrepancy between the clinic letter and 
patient’s medication list. Clinic Letter 
says 300 mg Venlafaxine versus 337.5 
mg on the surgeries medication list. 
Pharmacist 
changed to acute 
so a GP would 
have to see it if 
she requested 
again. 
Category D Minor 
3 
(IDL) 
Only first page of clinic letter received 
(1/2). 
Pharmacist went 
forward with MR. 
Category A N/A 
4  
(IDL) 
1. Lisinopril was omitted from the 
discharge letter. 
Sent on to GP to 
look at. 
Category D Serious 
4* 
(IDL) 
2. Isosorbide Mononitrate has not been 
reordered by patient since May, may be 
causing headache, and it is still on 
repeat.  
 
Sent on to GP to 
look at. 
Category E Serious 
5 
(Clinic 
Letter) 
Discharge letter includes cetirizine; 
cetirizine not on repeat, only received 
once in march.  
Email sent on to 
the physician 
regarding other 
potential conflicts 
found in the letter. 
Category C Minor 
6 
(Clinic 
Letter) 
Unclear to pharmacist how the patient 
has been reducing their dose of steroid 
by 1 mg while the patient only gets 5mg 
tablets. 
Pharmacist 
attempted to call 
patient. 
Category E Significant 
7 
(Clinic 
Letter) 
Zolpidem dose was wrong in the letter in 
comparison to the current repeat. It is 
expected that the letter reflects the actual 
amount he is taking (half of a 7.5) while 
the chart itself only says 7.5mg.  
 
Pharmacist decide 
they had missed 
the (1/2) tablet 
instructions. 
Category C Significant 
8 
(Clinic 
Letter) 
Miscommunication about directions on 
the eye drop, two drops to right eye 
versus 1 drop to both eyes.  
 
Pharmacist 
initiated follow up 
with physician 
Category D Serious 
9 
(Clinic 
Letter) 
No dose listed on the letter (Paglaflozin). 
 
Pharmacist chose 
25 mg once daily 
 
Category D Serious 
10 
(Clinic 
Letter) 
No dose or duration 
(Dexamethasone/neomycin) 
 
Pharmacist 
initiated follow up 
Category D Significant 
11 
(IDL) 
Patient usually on Pizotifen 500 
micrograms, listed as 20MG in letter. 
 
Pharmacist left at 
500 mcg.  
Category G Potentially 
Lethal 
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